Designated Approvals
Some of the new agents addressed later, like the majority of drugs that receive FDA approval for marketing, have gone through a very, very long process of development steps and several clinical trials. However, for some of these drugs, the approval process has been expedited according to their special designation. When a drug is in the development phase and shows exceptional promise above what is currently available for a rare disease or a potentially fatal disease, that drug may receive a special FDA designation. Priority review designation is given to a drug for a serious condition that shows signifi cant improvement in both safety and effectiveness over current available treatment. Orphan drug designation is assigned to drugs intended to treat very rare diseases. This designation allows for development and marketing incentives. Accelerated approval designation allows for faster approval and review for drugs that appear to fi ll unmet needs for serious conditions or will be a substantial improvement over available therapy. When the FDA issues a new drug approval, that notice will usually identify any special designation ( FDA, 2015 ) .
Selected Recent FDA Drug Approvals

D IABETES
Three new agents to treat diabetes were approved for marketing. Two of these are new forms of insulin approved for use with both Types 1 and 2 diabetes. Tresiba (insulin degludec) is an ultralong-acting insulin analogue and Ryzodeg 70/30 (insulin degludec and insulin aspart) is a combination of an ultralong-acting insulin and a short-acting insulin. Both of these products may help persons with diabetes achieve better glucose control when used as an adjunct to regular insulin. Both come in adjustable dose pens, and dosing is highly individual. Primary adverse effects are hypoglycemia. A third new agent for diabetic control for patients with Type 2 diabetes is a combination agent Synjardy (empaglifl ozin and metformin). Empaglifl ozin acts in renal tubules to increase urinary glucose excretion, and metformin decreases glucose production and increases target cell insulin sensitivity. This is an oral agent taken twice daily with food. There are four combination dosages available, and choice of dose is based on a patient's prior drug schedule, effectiveness, and tolerance. Caution must be used in patients with renal impairment, and renal function should be assessed regularly. This drug carries a warning for risk of lactic acidosis, which is a rare but serious complication that can result from metformin accumulation. As with any diabetic medication, hypoglycemia can occur, especially if used concurrently with another antidiabetic medication.
In the past year, the Federal Drug Administration (FDA) approved many new drugs for treating a wide variety of patient health problems. In a previous article, examples of approvals for the early part of last year were addressed. In this article, selected new FDA approvals through January 2016 are discussed. Nurses who are knowledgeable and informed about these new drugs will be able to answer patients' questions, clarify misunderstandings, and reduce the potential for medication misadventures.
O NCOLOGY
In the ongoing effort to improve the outlook for patients with cancer, several new products have been approved. Two agents approved for non-small cell lung cancer (NSCLC) include Portrazza (necitumumab) and Tagrisso (osimertinib). Portrazza is administered intravenously as an addition to a regimen of gemcitabine and cisplatin. It has been shown, in clinical studies, to extend the overall survival for those with metastatic squamous NSCLC by an average of 11 months. Common side effects are skin rash and hypomagnesemia (magnesium levels must be assessed on a regular basis and patients educated about signs of hypomagnesemia). Tagrisso was approved under the accelerated approval program as breakthrough therapy with priority designation. It is an oral agent that targets a mutation in the epidermal growth factor receptor that is involved in growth and spread of cancer cells in NSCLC. In clinical studies with Tagrisso, more than 50% of persons with NSCLC experienced a reduction in tumor size. Common side effects are skin rash and nail infections. Serious side effects include infl ammation of the lungs and cardiac injury. New approvals for treating myeloma include Darazlex (daratumumab) and Ninlaro (ixazomib). Darzalex (daratumumab) is a monoclonal antibody for patients with multiple myeloma who have previously been treated with at least three other treatments including a protease inhibitor. Darzalex acts by binding to a molecule expressed on the myeloma cells, causing cell death. This is an intravenous medication to be infused weekly, then every 2 weeks, and then every 4 weeks until disease progresses. Patients must be watched closely during infusions for occurrence of a severe infusion reaction. Common side effects include nausea, fever, and upper respiratory infection. Ninlaro, granted both priority review and orphan drug designation, is the fi rst oral protease inhibitor that is available for people whose multiple myeloma recur or who did not respond to at least one prior therapy. It is given on a 7-day cycle and approved for combination with lenalidomide (another approved multiple myeloma treatment) and dexamethasone. Side effects include gastrointestinal (GI) disturbance, peripheral neuropathy, and peripheral edema.
H EPATITIS C
Hepatitis C is a blood-borne disease that causes infl ammation of the liver and usually has no acute symptoms until liver damage is apparent with decreased liver function, cirrhosis, or liver cancer. Moreover, treatment of hepatitis C was long, tiresome, and usually only partially successful: Finding an oral treatment of hepatitis C that would be effective before extensive liver damage occurred was a major challenge. Zepatier (elbasvir/ grazoprevir), which was granted breakthrough therapy designation, is an oral treatment option for patients with chronic hepatitis C Genotypes 1 (the most common) and 4 (less common) that have no liver impairment. This combination agent is an oral tablet taken once a day for 12-16 weeks. It can be used with or without ribavirin, depending on the genotype of the patient's hepatitis C. Most common side effects with Zepatier alone are fatigue, headache, and nausea and with ribavirin are anemia and headache. Rare instances of acute elevation in liver enzymes occur, usually after several weeks of treatment, so blood tests should be done before starting therapy and periodically during treatment.
H YPERKALEMIA
Veltassa (patiromer) has been approved to treat hyperkalemia. For patients with chronic diabetic kidney disease and those with heart failure (especially those taking any medication that inhibits the renin-angiotensinaldosterone system), chronically high levels of potassium can occur. These excessively high levels of potassium can lead to cardiac changes, which may potentially be fatal. Veltassa is nonabsorbable and acts by binding to potassium in the GI tract. Initial daily dose is 8.4 g of Veltassa powder mixed with water and then adjusted upward according to serum potassium and target levels. Because Veltassa has a delayed onset of action, it should not be used in an emergency of life-threatening hyperkalemia. Most common adverse effects are decreased magnesium level, constipation, GI upset, and constipation or diarrhea. Veltassa carries a black box warning that any other orally administered medication should be taken at least 6 hours apart from Veltassa.
H YPERLIPIDEMIA
Repatha (evolocumab) is an adjunctive therapy for patients with primary inherited heterozygous or homozygous hyperlipidemia and known cardiovascular disease who cannot get their low-density lipoprotein (LDL) levels under control with maximum tolerated doses of statins and strict diet. In clinical studies, when evolocumab was added to standard therapy, LDL cholesterol levels were signifi cantly lowered and rate of cardiovascular events were less than half of events in those who had not had evolocumab added to their treatment. This is monoclonal antibody that is only the second drug in a class known as PCSK9 inhibitors. These drugs work in the liver to target the PCSK9 protein that reduces the number of receptors that remove LDL cholesterol from the liver. Thus, by blocking PCSK9, more receptors are available to remove LDL from the blood. Repatha is administered by subcutaneous injection every 2 weeks or once a month, with frequency and dose according to the type of hyperlipidemia. Most common side effects are nasopharyngitis, respiratory tract infection, infl uenza symptoms, back pain, or injection site reactions. Serious, but rare, allergic reactions have occurred.
H YPOACTIVE S EXUAL D ESIRE D ISORDER
Addyi (fl ibanserin) is approved for premenopausal women with a diagnosis of HSDD, which is characterized by low sexual desire that causes signifi cant interpersonal diffi culty and is not due to a coexisting medical or psychiatric condition, problems in the relationship, or effects of other medications developing in a patient who previously had no problems with sexual desire. Flibanserin (originally designed as an antidepressant) acts on certain serotonin and dopamine receptors, but how it affects HSDD is not known. The most common side effects are dizziness, somnolence, nausea, or fatigue. However, Addyi carries a black box warning that any amount of alcohol with Addyi may cause fatal hypotension. In addition, both prescribers and patients are required to undergo a REMS (risk and mitigation) certifi cation process and patients must complete a written agreement to abstain from alcohol. Contraindications include anyone with liver impairment or anyone taking CYP3A4 inhibitors.
C HRONIC O BSTRUCTIVE L UNG D ISEASE
One of the goals of treating chronic obstructive lung disease (COPD) is to not only to slow the progression of the disease but also to improve the symptoms so that patients can have a better quality of life. Utibron
Neohaler (indacaterol/glycopyrrolate inhaled) was approved for the long-term maintenance therapy for people with COPD, including bronchitis and/or emphysema. This is a combination of a long-acting β 2 agonist that causes relaxation of bronchial smooth muscles and an anticholinergic that produces bronchodilation that helps airfl ow obstruction in patients with COPD. Utibron comes in a capsule form to be used only in an Utibron inhaler twice daily on a regular basis. It should not be used as a rescue inhaler to treat sudden symptoms of COPD and should not be used to treat asthma; In fact, Utibron carries a black box warning about not using for asthma. Caution should be used in the presence of cardiovascular disease, diabetes, narrow angle glaucoma, seizure disorders, severe renal impairment, or urinary tract problems. Serious drug-drug interactions can occur with other anticholinergics or longacting β 2 agonists. Common side effects include sore throat, runny nose, elevated blood pressure, and back pain.
A STHMA
Some patients with chronic asthma can be fairly stable without a lot of severe acute asthma attacks. Others have frequent severe life-threatening attacks that result in hospitalization. For those patients 12 years and older who have frequent exacerbations (severe asthma attacks) despite their current medication, Nucala (mepolizumab) offers an additional therapy. Mepolizumab is a monoclonal antibody that is administered subcutaneously by a healthcare professional once every 4 weeks. It acts to lessen severe asthma attacks by reducing the blood levels of eosinophil A-type white blood cells that contribute to the development of asthma. In clinical trials, patients receiving Nucala along with their regular medicines had fewer severe attacks with hospitalization and a longer time between exacerbations. They also were able to reduce their daily doses of oral corticosteroids while maintaining asthma control. Hypersensitivity allergic reactions are rare but can occur even hours or days after injection, and rare herpes zoster infections have occurred. The most common side effects include headache, back pain, fatigue, and injection site reactions.
H EREDITARY F ACTOR X D EFICIENCY
Factor X is a vital component of the coagulation complex so that a defi ciency of Factor X can lead to severe bleeding episodes. Hereditary Factor X defi ciency is very rare, and, until now, there was no replacement therapy except fresh frozen plasma or plasma-derived prothrombin complex concentrates. Coagadex (Factor X, human) is a concentrate of Factor X derived from human plasma that received both orphan product and fast track designation. It is approved for use with patients (older than 12 years) who have hereditary Factor X defi ciency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild Factor X defi ciency. Coagadex comes as a powder to be reconstituted with sterile water and administered intravenously: Dose and frequency depend on severity of Factor X defi ciency, location and extent of
